MTI Biotech Inc.
Privately held: no public share price · United States
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 1/2 | Dicarbonyl scavenging (isoketal/isolevuglandin)Small molecule | Alzheimer's Disease |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (1)
December 2028 (1)
Est. primary completion 2028-12-30 · NCT06432166 · CT.gov ↗
What to watch
Financial reports
No financial reports recorded.